PULSE CYCLOPHOSPHAMIDE THERAPY FOR REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA

被引:0
|
作者
REINER, A
GERNSHEIMER, T
SLICHTER, SJ
机构
[1] PUGET SOUND BLOOD CTR,DIV MED & RES,SEATTLE,WA 98104
[2] UNIV WASHINGTON,SCH MED,DIV HEMATOL,SEATTLE,WA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autoimmune thrombocytopenic purpura (AITP) is generally a chronic disorder in affected adults. Twenty-five percent of these patients will become refractory to routine therapy (corticosteroids and splenectomy), as well as most other available agents. Intravenous pulse cyclophosphamide therapy was used to treat 20 patients with severe refractory AITP who had previously failed to achieve a sustained remission with a mean of 4.8 agents (range 2 to 8). Patients received 1 to 4 doses (mean 2.0) of 1.0 to 1.5 g/m(2) intravenous cyclophosphamide per course. Of the 20 patients treated with pulse cyclophosphamide therapy, 13 patients (65%) achieved a complete response (CR), four (20%) a partial response (PR), and three patients (15%) failed to respond. Of the 13 complete responders, eight have remained in remission with stable platelet counts during followup intervals of 7 months to 7 years (median 2.5 years). Five patients developed recurrent AITP 4 months to 3 years following a CR. Of these, two patients responded to subsequent courses of pulse cyclophosphamide therapy with current remissions of 1 and 4 years. Of the four patients who obtained a PR, two remain in partial remission after 10 months and 4 years; one relapsed after 18 months and, after retreatment, is still in remission at 6 months. Of the patient characteristics examined, duration of disease was most strongly associated with response to pulse cyclophosphamide. Side-effects of treatment included neutropenia (three patients, one of whom developed staphylococcal sepsis), acute deep venous thrombosis (two patients), and psoas abscess (one patient). Intravenous pulse cyclophosphamide should be strongly considered in the treatment of patients with refractory AITP. There is a relatively low incidence of side-effects, and it can be administered easily on an out-patient basis. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:351 / 358
页数:8
相关论文
共 50 条
  • [41] TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIC PURPURA
    OZSOYLU, S
    NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (11): : 760 - 760
  • [42] DAPSONE FOR AUTOIMMUNE THROMBOCYTOPENIC PURPURA
    GODEAU, B
    OKSENHENDLER, E
    BIERLING, P
    AMERICAN JOURNAL OF HEMATOLOGY, 1993, 44 (01) : 70 - 72
  • [43] AUTOIMMUNE THROMBOCYTOPENIC PURPURA IN PREGNANCY
    MOISE, KJ
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1991, 34 (01): : 51 - 63
  • [44] THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIC PURPURA
    CAJOZZO, A
    PERRICONE, R
    MINERVA MEDICA, 1982, 73 (18) : 1179 - 1183
  • [45] IMMUNODEFICIENCY AND AUTOIMMUNE THROMBOCYTOPENIC PURPURA
    JACOBS, P
    HOUGAARD, M
    SOUTH AFRICAN MEDICAL JOURNAL, 1975, 49 (05): : 134 - 134
  • [46] IDIOPATHIC (AUTOIMMUNE) THROMBOCYTOPENIC PURPURA
    HUNDLEY, JM
    JOURNAL OF MEDICAL TECHNOLOGY, 1986, 3 (05): : 285 - 290
  • [47] PREGNANCY AND AUTOIMMUNE THROMBOCYTOPENIC PURPURA
    LOURENCO, DM
    VIGNAL, CV
    KERBAUY, J
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1299 - 1299
  • [48] Autoimmune (idiopathic) thrombocytopenic purpura
    Karpatkin, S
    LANCET, 1997, 349 (9064): : 1531 - 1536
  • [49] AUTOIMMUNE-THROMBOCYTOPENIC-PURPURA
    KARPATKIN, S
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1971, 261 (03): : 126 - +
  • [50] Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura
    Jumana H. Albaramki
    Juliana Teo
    Stephen I. Alexander
    Pediatric Nephrology, 2009, 24 : 1749 - 1752